KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$4.1 million.

  • Neogenomics' Change in Accured Expenses fell 13986.77% to -$4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$15.7 million, marking a year-over-year decrease of 26874.93%. This contributed to the annual value of -$15.7 million for FY2025, which is 26874.93% down from last year.
  • Per Neogenomics' latest filing, its Change in Accured Expenses stood at -$4.1 million for Q4 2025, which was down 13986.77% from $2.8 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Change in Accured Expenses registered a high of $13.6 million during Q2 2024, and its lowest value of -$23.0 million during Q1 2025.
  • For the 5-year period, Neogenomics' Change in Accured Expenses averaged around $1.0 million, with its median value being $2.5 million (2022).
  • Over the last 5 years, Neogenomics' Change in Accured Expenses had its largest YoY gain of 48005.43% in 2021, and its largest YoY loss of 64895.05% in 2021.
  • Neogenomics' Change in Accured Expenses (Quarter) stood at -$3.7 million in 2021, then surged by 158.12% to $2.2 million in 2022, then skyrocketed by 158.93% to $5.6 million in 2023, then skyrocketed by 84.64% to $10.3 million in 2024, then plummeted by 139.87% to -$4.1 million in 2025.
  • Its Change in Accured Expenses stands at -$4.1 million for Q4 2025, versus $2.8 million for Q3 2025 and $8.6 million for Q2 2025.